5-7 December 2017

London, UK

Register here

Day One
Wednesday, 6th December 2017

Day Two
Thursday, 7th December 2017

08.00
Registration and Networking

08.30
Chair’s Opening Remarks

Optimising Preclinical Data Packages to Improve Translational Research

08.40
Tumour Microenvironment, Heterogeneity and clinically relevant models

  • Rajendra Kumari General Manager & Chief Scientific Officer, Crown Bioscience UK Ltd

Synopsis

  • Addressing the demand for clinically relevant models for understanding disease progression & identifying responsive patient populations
  • Developing 3D systems and PDX modelling to enhance translational success
  • Adopting the right models across oncology therapeutics

 

09.10
How to Achieve Predictability in Development and Monitoring of Tumour Microenvironment Directed Therapies?

Synopsis

Session 11 till 12

09.40
The Application of Network Driven Drug Discovery to Identify Novel First in Class Small Molecules Across a Variety of Oncology Indications

Synopsis

  • Combining a unique computer-based platform with biological expertise to create and analyse in silico network models of disease
  • Network Driven Drug Discovery providing rational choices for further testing in in vitro phenotypic screening
  • Applying in vivo preclinical models to identify novel lead molecules in oncology drug discovery

10.10
Utilising Multicellular 3D Models for Preclinical Drug Discovery

Synopsis

  • Primary 3D cell cultures from patient material
  • Addition of monocytes or fibroblasts to identify a potential trophic role
  • Influence of microenvironment on stemness
  • Transplantation of multicellular spheres to create tumours with microenvironment

10.40
Speed Networking

11.10
Morning Refreshments

Minimising the Translational Gap from Preclinical to Clinical through Next Generation In Vivo Models

11.40
Incorporating CRISPR into the pre-clinical testing of TCR-based biologic drug candidates

Synopsis

  • Analysing the need of predicting off-target effects in the preclinical testing of tumour immunotherapy candidates
  • Overview on validated preclinical tests to assess potency and cross-reactivity
  • Applying CRISPR to preclinical: benefits and challenges.

12.10
INOVOTION Technology for Oncology Drug Discovery: Early In Vivo Identification of Low Value Molecules

Synopsis

• How to use INOVOTION technology to open new perspectives of in vivo screening for
anti-caner treatments
• Why chick embryo model has several advantages for drug discovery in oncology
• Chick embryo model fills the gap between in vitro and mouse model but is it possible to
predict mouse data from chick embryo results

12.40
Remodelling Barrett’s Metaplasia in a Novel In Vivo Organoid Model

Synopsis

Session 11 till 12

13.10
Networking and Lunch

Utilising More Clinically Relevant Humanised Mouse Models

14.10
Role of Genetically Engineered Mouse Models in Drug Discovery

Synopsis

  • Key challenges using classic syngeneic models for drug discovery
  • Potential for using genetically engineered mouse models to support understanding of dose and schedule
  • Looking to the future: How can GEMMs be used?

14.40
Utilising Sophisticated Mouse Models to Better Understand the Pathways and Mechanisms of Emerging Immune Therapies

  • James Keck Senior Director In Vivo Pharmacology, Jackson

Synopsis

  • Understand how animal models can provide accurate in vivo conditions to mimic the natural tumour environment
  • Hear the latest case studies in the use and relevance of humanised mice
  • Explore how to successfully use humanised models to select combinations of immunotherapies

15.10
Developing an In Vivo model for Proof of Concept of small molecules targeting the myeloid compartment

Synopsis

Session 11 till 12

15.40
How To Advance PDX Tumour Biology Platforms for Drug Advancement

  • Neal Goodwin Vice President Corporate Research, Champions Oncology

Synopsis

  • Large collections of PDX models allow for more resolute efficacy predictions and the discovery of new therapeutic targets
  • Why creating robust systems of myeloid engraftment allow for expanded PDX screening with a wider scope of therapeutics agents
  • Combining clinical trials with companion PDX studies to guide follow-on trial design

16.10
Afternoon Refreshments & Poster Session

16.40
Humanised Mouse Models for Immunotherapy Pipeline Advancement

  • Mario Perro Group Leader of Preclinical Imaging and Histology Core, Pharmacology Department , Roche

Synopsis

  • Overview of different classes of humanised mouse models
  • Advantages and pitfalls of humanised mouse models
  • In vivo profiling of cancer immunotherapies in humanised mouse models

17.10
PDX Models Recapitulate Clinical Tumour Progression

Synopsis

Session 11 till 12

17.40
The Repositive PDX Resource – A Collaborative Resource Providing Improved Access to Find and Select PDX Models From World-wide PDX Vendors

Synopsis

  • Overview of Repositive and its mission to help researchers help patients faster
  • Introduction to the Repositive PDX Platform, its features and the benefits to simplify workflows for PDX researchers and PDX vendors
  • A vision for the future: partnerships and collaboration

17.55
Chairperson’s Closing Remarks

18.00
Drinks Reception hosted by Crown Bioscience